Allecra Therapeutics

Novel treatments to combat multi drug-resistant bacterial infections.

Allecra Therapeutics, a clinical stage biopharmaceutical company, was established in 2013 and is dedicated to the development of novel treatments to combat multi drug-resistant bacterial infections.

Allecra has developed EXBLIFEP, which got both FDA and EMA approval for the treatment of cUTI and is marketed by partner Advanz in Europe and by partner Acino in Gulf Cooperation Council countries and South Africa.